These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36321578)

  • 1. Vaccination against COVID-19 does not lead to exacerbation in patients with myasthenia gravis.
    Breiner A; Bourque PR
    Muscle Nerve; 2023 Jan; 67(1):1-2. PubMed ID: 36321578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccination in myasthenia gravis: safe, but predictors of disease exacerbation yet to be determined.
    Kim S; Eun MY; Seok HY
    Neurol Sci; 2023 May; 44(5):1503-1504. PubMed ID: 36808584
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of mRNA COVID-19 vaccines in patients with well-controlled myasthenia gravis.
    Gamez J; Gamez A; Carmona F
    Muscle Nerve; 2022 Nov; 66(5):612-617. PubMed ID: 36029224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis.
    Urra Pincheira A; Alnajjar S; Katzberg H; Barnett C; Daniyal L; Rohan R; Bril V
    Muscle Nerve; 2022 Nov; 66(5):558-561. PubMed ID: 35673960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-onset myasthenia gravis after mRNA SARS-CoV-2 vaccination: a case series.
    Fanella G; Baiata C; Candeloro E; Toscano G; Colnaghi S; Mauri M; Cariddi LP; Rebecchi V; Solazzo F; Banfi P; Piatti M; Ferrarese C; Versino M
    Neurol Sci; 2022 Oct; 43(10):5799-5802. PubMed ID: 35870026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 vaccination and new-onset myasthenia gravis: A report of 7 cases and review of the literature.
    Ramdas S; Hum RM; Price A; Paul A; Bland J; Burke G; Farrugia M; Palace J; Storrie A; Ho P; Standing E; Lilleker JB; Jungbluth H
    Neuromuscul Disord; 2022 Oct; 32(10):785-789. PubMed ID: 36130855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].
    Wang SH; Xie YC; Jiang B; Zhang JY; Qu Y; Zhao Y; Li Y; Qiao SS; Xu CL
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(17):1283-6. PubMed ID: 24029473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Remdesivir in Myasthenia gravis and COVID-19.
    Peters BJ; Rabinstein AA; DuBrock HM
    Pharmacotherapy; 2021 Jun; 41(6):546-550. PubMed ID: 33835512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.
    Ramaswamy SB; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):361-364. PubMed ID: 32508329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. To Be or Not To Be Vaccinated: That Is a Question in Myasthenia Gravis.
    Zhou Q; Zhou R; Yang H; Yang H
    Front Immunol; 2021; 12():733418. PubMed ID: 34603311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs that may exacerbate myasthenia gravis.
    Adams SL; Mathews J; Grammer LC
    Ann Emerg Med; 1984 Jul; 13(7):532-8. PubMed ID: 6742556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Exacerbation of myasthenia gravis by pefloxacin].
    Vial T; Chauplannaz G; Brunel P; Leriche B; Evreux JC
    Rev Neurol (Paris); 1995 Apr; 151(4):286-7. PubMed ID: 7481384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)].
    Cadisch R; Streit E; Hartmann K
    Schweiz Med Wochenschr; 1996 Feb; 126(8):308-10. PubMed ID: 8701248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
    Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
    Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients.
    Sansone G; Bonifati DM
    J Neurol; 2022 Aug; 269(8):3965-3981. PubMed ID: 35503373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies.
    Dalakas MC
    Curr Opin Neurol; 2020 Oct; 33(5):545-552. PubMed ID: 32833750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BNT162b2 mRNA COVID-19 vaccine three-dose safety and risk of COVID-19 in patients with myasthenia gravis during the alpha, delta, and omicron waves.
    Doron A; Piura Y; Vigiser I; Kolb H; Regev K; Nesher N; Karni A
    J Neurol; 2022 Dec; 269(12):6193-6201. PubMed ID: 35907046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Problems in the administration of antibiotics to the patients with myasthenia gravis].
    Onishi A; Shida K; Kuroiwa Y
    Naika; 1970 Nov; 26(5):926-9. PubMed ID: 5529430
    [No Abstract]   [Full Text] [Related]  

  • 19. Acute onset ocular myasthenia gravis after COVID-19 vaccination: correspondence.
    Mungmunpuntipantip R; Wiwanitkit V
    Orbit; 2022 Oct; 41(5):661. PubMed ID: 35639541
    [No Abstract]   [Full Text] [Related]  

  • 20. Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
    Mimori M; Komatsu T; Maku T; Mitsumura H; Iguchi Y
    Neurol Sci; 2022 Jul; 43(7):4081-4083. PubMed ID: 35364770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.